▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1448 by analyst upside · 2026-10-16
LMRI
Lumexa Imaging Holdings, Inc.
Healthcare · Market Cap $1B · P/E 0x
ANALYST PRICE TARGET
+63.9%
implied upside to consensus target
Current Price $10.78
Consensus Target $17.67
Bull Target $23.0
Bear Target $13.0
Analysts Covering 9
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
7
Hold
0
Sell
0
52-Week Low $6.45
52-Week High $19.45
YTD Return -38.6%
FUNDAMENTALS
Market Cap $1B
P/E Ratio (TTM) N/A
Forward P/E 12.1x
EPS (TTM) $-0.37
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $1.0B
Profit Margin -2.7%
52-WEEK RANGE
52-Week Low $6.45
52-Week High $19.45
Current Price $10.78
Bear Target $13.0
Bull Target $23.0
● Now $10.78 ● Target $17.67
TRADING DATA
Avg Volume 417K
YTD Return -38.6%
Analyst Count 9
Consensus Buy
Upside to Target +63.9%
Last Updated 2026-10-16

ANALYST SUMMARY

Lumexa Imaging Holdings, Inc. (LMRI) is currently trading at $10.78 with a Wall Street consensus price target of $17.67, implying potential upside of 63.9% over the next 12 months. 9 analysts currently cover LMRI, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $23.0, while the most cautious has a target of $13.0.

LMRI operates in the Healthcare sector with a market capitalisation of $1B. The stock is down 38.6% year-to-date and is currently trading near the lower end of its 52-week range of $6.45 – $19.45.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for LMRI, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Truist Securities ● Initiated
Buy 2026-10-05 Building track record
Keybanc ● Initiated
Overweight 2026-09-25 Building track record
Barclays - Reiterated
Overweight → Overweight 2026-08-28 Building track record
Barclays - Reiterated
Overweight → Overweight 2026-05-20 Building track record
Barclays - Reiterated
Overweight → Overweight 2026-04-14 Building track record
Raymond James ↑ Upgrade
Outperform → Strong Buy 2026-02-09 Building track record
Raymond James ● Initiated
Outperform 2026-01-05 Building track record
Barclays ● Initiated
Overweight 2026-01-05 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
56
out of 100
Coverage depth
18/30
Consensus clarity
11/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →